Home » Stocks » Bio-Techne

Bio-Techne Corp (TECH)

Stock Price: $263.73 USD -4.15 (-1.55%)
Updated Aug 6, 2020 12:01 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 10.08B
Revenue (ttm) 754.52M
Net Income (ttm) 186.91M
Shares Out 38.22M
EPS (ttm) 4.76
PE Ratio 55.40
Forward PE 52.36
Dividend $1.28
Dividend Yield 0.49%

Stock Quote

Trading Day Aug 6, 2020
Last Price $263.73
Previous Close $267.87
Change ($) -4.15
Change (%) -1.55%
Day's Open 270.47
Day's Range 262.34 - 271.22
Day's Volume 32,595
52-Week Range 155.17 - 286.68

More Stats

Market Cap 10.08B
Enterprise Value 10.32B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date May 8, 2020
Shares Outstanding 38.22M
Float 38.01M
EPS (basic) 4.89
EPS (diluted) 4.76
FCF / Share 4.45
Dividend $1.28
Dividend Yield 0.49%
Earnings Yield 1.80%
FCF Yield 1.69%
Payout Ratio 26.20%
Shares Short 589,993
Short Ratio 2.95
Short % of Float 1.67%
Beta 1.14
PE Ratio 55.40
Forward PE 52.36
P/FCF Ratio 59.19
PS Ratio 13.36
PB Ratio 8.15
Revenue 754.52M
Operating Income 161.37M
Net Income 186.91M
Free Cash Flow 170.31M
Net Cash -237.80M
Net Cash / Share -6.22
Gross Margin 63.25%
Operating Margin 21.39%
Profit Margin 24.80%
FCF Margin 22.57%
ROA 5.22%
ROE 15.34%
ROIC 27.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 4
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$255.88*
(-2.97% downside)
Low
211
Current: $263.73
High
320
Target: 255.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue714643563499452358311315290269
Revenue Growth11.04%14.21%12.82%10.34%26.41%15.19%-1.27%8.48%7.77%-
Gross Profit473432375337307251231236225214
Operating Income147136121151147160158166163156
Net Income96.0712676.09104108111113112112110
Shares Outstanding37.7837.4837.3137.1937.1036.8936.8436.9437.1037.26
Earnings Per Share2.473.312.032.802.893.003.053.043.022.94
EPS Growth-25.38%63.05%-27.5%-3.11%-3.67%-1.64%0.33%0.66%2.72%-
Dividend Per Share1.281.281.281.281.271.231.181.111.071.03
Dividend Growth0%0%0%0.79%3.25%4.24%6.31%3.74%3.88%-
Operating Cash Flow182170144144139137124127127111
Capital Expenditures-25.41-20.93-15.18-16.90-19.91-13.82-22.45-6.02-3.63-4.64
Free Cash Flow156149129127119123101121124107
Cash & Equivalents16618215895.84111363333269141139
Total Debt50533934495.2677.0212.95----
Net Cash / Debt-339-157-1860.5833.90350333269141139
Assets1,8841,5931,5581,1301,063862778719618519
Liabilities71951460925021667.2340.5644.8831.5517.02
Book Value1,1661,079950879847795738674586502
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bio-Techne Corp
Country United States
Employees 2,200
CEO Charles R. Kummeth

Stock Information

Ticker Symbol TECH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TECH
IPO Date February 9, 1989

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. Bio-Techne Corporation has partnership with Kantaro Biosciences to develop and scale production of COVID-19 serology test. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.